Key MessageOur prospective study demonstrated that early circulating tumour DNA dynamics predict progression-free survival with high accuracy in an independent validation series of metastatic breast cancer (mBC) patients on paclitaxel with or without capivasertib. We show early dynamics anticipated the outcome of the randomised study, correctly refuting the hypothesis that *PIK3CA* mutant ER+ mBC would have higher sensitivity to capivasertib in combination with Paclitaxel.

Introduction
============

Dynamic changes in the level of circulating tumour DNA (ctDNA) early on treatment have the potential to act as a surrogate for treatment response across multiple tumour types \[[@mdz085-B1]\]. The level of ctDNA is principally a function of two factors, tumour bulk and tumour cell turnover \[[@mdz085-B4]\], which results in the level of ctDNA falling rapidly in tumours responding to treatment. Prior research has shown that early changes in ctDNA levels may predict response and progression-free survival (PFS) \[[@mdz085-B9]\], including targeted therapies encompassing CDK4/6 inhibitors \[[@mdz085-B12]\], human epidermal growth factor receptor 2 (HER2)-targeted therapies \[[@mdz085-B13]\], and chemotherapy \[[@mdz085-B14]\]. The assessment of early ctDNA dynamics is to potentially identify, before radiographic change in tumour size, which cancers are not responding adequately to therapy and allow adaption of treatment to avoid symptomatic progression \[[@mdz085-B15]\]. Dynamic assessment may also facilitate early drug development, providing an early assessment of drug efficacy and identification of biomarkers of response \[[@mdz085-B7], [@mdz085-B18], [@mdz085-B19]\].

Predicting the outcome of therapy early would allow adaptive changes to treatment to improve outcome. Prior work using circulating tumour cells (CTC) counts, applying a fixed cut-off \[[@mdz085-B20]\], failed to identify a patient population who would benefit from a change in chemotherapy \[[@mdz085-B21]\]. Interrogating ctDNA gives substantially greater dynamic range and sensitivity than CTC enumeration \[[@mdz085-B1]\] allowing more exact definition of which patients are resistant to therapy, in part allowing comparison of on-treatment levels with baseline to allow for the substantial variation in baseline ctDNA levels.

Here, we assessed the potential of dynamic ctDNA change in a randomised placebo-controlled phase II study. In the development cohort, we identified the optimal early time-point and cut-off to predict PFS on the first-line paclitaxel chemotherapy given in combination with the AKT inhibitor capivasertib (AZD5363). We subsequently validated these criteria in the randomised part of the study, demonstrating that early ctDNA dynamics was a strong surrogate for PFS and that early ctDNA change analysis predicted there was no difference between the treatment arms reported by Turner et al. \[[@mdz085-B22]\].

Materials and methods
=====================

Study design
------------

The BEECH study (NCT01625286) was a phase I/II trial consisting of part A, a safety run in of capivasertib in combination with paclitaxel in women with advanced or metastatic breast cancer and part B, a randomised double-blind phase II study of capivasertib or placebo in combination with paclitaxel in women with advanced or metastatic ER+/HER2- breast cancer receiving chemotherapy for the first time in the metastatic setting. Maintenance endocrine therapy was not allowed. Treatment regimens are reported in the related article by Turner et al. \[[@mdz085-B22]\]. Patients were allocated to the *PIK3CA*+ stratum if a mutation was identified either in tissue or ctDNA by the cobas^®^*PIK3CA* mutation test (Roche Diagnostics, Basel, Switzerland, Basel, Switzerland).

Sample collection + processing
------------------------------

Five millilitre blood was collected for exploratory ctDNA analysis at designated timepoints throughout the study (Figure [1](#mdz085-F1){ref-type="fig"}). Plasma was separated within 2 hours of venesection and stored at −80°C. Extracted DNA was quantified by digital droplet PCR (ddPCR) using a Taqman copy number reference assay for RNAse P (Thermo Scientific, UK) as described previously \[[@mdz085-B17]\] and stored at −20°C before analysis.

![Overview of BEECH study exploratory analysis. (A) Schema of plasma collection during the BEECH trial for both development part A and validation part B cohorts. Red arrows indicate part A sampling only, blue part B sampling only and purple part A and B shared timepoint sampling. Tracking samples were collected on day 1 of each treatment cycle. (B) CONSORT diagrams of part A and part B exploratory plasma baseline analysis.](mdz085f1){#mdz085-F1}

Baseline plasma mutation identification
---------------------------------------

Baseline samples \[screening and/or cycle 1 day 1 (C1 D1) and/or cycle 1 day 2 (C1 D2)\] from patients who consented to ctDNA analysis was subject to sequencing for mutations to subsequently track in plasma samples on treatment. Sequencing also validated *PIK3CA* mutations identified by the cobas^®^*PIK3CA* mutation test with high agreement ([supplementary Table S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Full sequencing methodology available in [supplementary Methods](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online along with the targeted panel details for part A ([supplementary Table S2](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online) and the targeted capture panel details for part B ([supplementary Table S3](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

Personalised digital PCR assay design and tracking
--------------------------------------------------

From baseline ctDNA sequencing, we identified likely somatic driver mutations and designed primers and probes for digital PCR analysis. Full assay design details ([supplementary Table S4](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online) and digital PCR methods available in [supplementary Methods](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online.

Circulating tumour DNA ratio analysis
-------------------------------------

For on-treatment digital PCR, the circulating tumour DNA ratio (CDR). Between on-treatment mutation fraction and baseline/screening mutation allele fraction was calculated for all timepoints. In part A, the optimal time-point to predict PFS within the first 4 weeks of treatment was established ([supplementary Methods](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology*).

The primary analysis of the study was, in the independent part B validation cohort, to compare PFS between patients with CDR28 (CDR at cycle 2 day 1, 28 days on treatment identified in part A) greater than the cut-off identified in part A (high ctDNA) and those with CDR28 lower than the cut-off (suppressed ctDNA). Analysis was conducted by Kaplan--Meier survival, with median comparison using the log rank test and hazard ratios from Cox proportional hazards model. Additional secondary analyses were to compare CDR28 between treatment arms, overall and in the *PIK3CA* mutant sub-population, with Mann--Whitney *U* test.

Lead-time on on-treatment ctDNA tracking
----------------------------------------

We established a 'rise from nadir' criteria to assess lead time by ctDNA from on-treatment tracking in patients who had initial ctDNA suppression. Patients defined as CDR28 high were determined to have a lead time from day 28 as they did not experience ctDNA suppression. A 'rise towards baseline' criteria was also devised. Full details for both criteria are available in [supplementary Methods](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology*.

Results
=======

Development of criteria for early assessment of response
--------------------------------------------------------

To develop criteria for the early dynamic ctDNA assessment, we intensively sampled 16 patients during the first 4 weeks of therapy on paclitaxel and capivasertib in part A of the BEECH trial (Figure [1](#mdz085-F1){ref-type="fig"}). Suppression of ctDNA in patients with long PFS became apparent after only 8 days of treatment (Figure [2](#mdz085-F2){ref-type="fig"}A), and C2D1 was identified as the optimal time-point for ctDNA change to discriminate patients with a long versus short PFS (Figure [2](#mdz085-F2){ref-type="fig"}A). In the part A development cohort, using a CDR threshold of 0.25 (established in Methods), the patients with a CDR \<0.25 had a substantially improved PFS compared with those without suppressed ctDNA (Figure [2](#mdz085-F2){ref-type="fig"}B, *P *=* *0.0003 log rank test). Tracking mutations through sequential samples, in patients with ctDNA suppression, at the start of each cycle demonstrated further falls to a nadir that was frequently undetectable, before a rise with lead-time over clinical progression (Figure [2](#mdz085-F2){ref-type="fig"}C). Conversely, in patients without ctDNA suppression, ctDNA remains high across the tracking samples before clinical progression, which occurred before the 12-week scan (Figure [2](#mdz085-F2){ref-type="fig"}D).

![Identification of optimal circulating tumour DNA (ctDNA) early timepoint for prediction of progression-free survival (PFS) length in the development cohort. (A) Circulating tumour DNA ratios (CDRs) at designated timepoints in the first 4 weeks of study treatment, separated by short and long PFS in study part A. Differing numbers in the long and short groups reflect missed sample collection timepoints in some patients. Long and short PFS was determined by a scan at 12 weeks on study, the time-point of the first scan in part A. C2D1 (CDR28) was the strongest predictive timepoint *P* = 0.0007, *P* value Mann--Whitney *U* test. (B) PFS for development part A patients split by CDR28 suppressed (CDR28\<0.25) versus CDR28 high. *P* value log rank test. (C) Longitudinal tracking of a *PIK3CA c.1624G\>A* (p.E542K) mutation in a patient classified as a long PFS by ctDNA demonstrating successful suppression of ctDNA before rise before progression. (D) Longitudinal tracking of a *TP53 c.815T\>C* (p.V272A) mutation in a patient classified as a short PFS by ctDNA demonstrating failure to suppress ctDNA in the first 4 weeks of treatment.](mdz085f2){#mdz085-F2}

Validation of ctDNA ratio to predict PFS
----------------------------------------

We independently validated early prediction of outcome from ctDNA dynamics, in the randomised part B of the BEECH study in 42 patients. Samples for ctDNA analysis were taken at screening and at C2D1, identified in part A as the optimal time point for early response assessment using ctDNA (CDR28). Mutation-specific ddPCR had excellent correlation with AZ300 panel allele fractions for mutations identified by sequencing ([supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology*). In the independent validation cohort, patients with a suppressed CDR28 had a median PFS 11.1 months and patients with a high CDR28 has a median PFS 6.4 months (hazard ratio = 0.20, 95% confidence interval 0.083--0.50, *P *\<* *0.0001, log rank test, Figure [3](#mdz085-F3){ref-type="fig"}A). We separately investigated patients randomised to paclitaxel and placebo, and paclitaxel and capivasertib, with no evident difference in prediction of PFS between both groups (Figure [3](#mdz085-F3){ref-type="fig"}B).

![Early ctDNA dynamics are a surrogate for progression-free survival (PFS) in the independent validation cohort. (A) PFS for validation cohort part B split by CDR28 suppressed (CDR28\<0.25) versus CDR28 high. *P* value log rank test. (B) PFS for high versus suppressed CDR28, stratified for placebo (top) and capivasertib (bottom) treatment arms. (C) Box plot of CDR28 by treatment arm for all patients and CDR28 for treatment arms subdivided by *PIK3CA* mutation status. Patients with undetectable ctDNA at C2 D1 were assigned an arbitrary low value for statistical analysis. *P* value from Mann--Whitney *U* test, not significant across the groups.](mdz085f3){#mdz085-F3}

Early ctDNA change predicted outcome of treatment randomisation
---------------------------------------------------------------

We next assessed the effect of capivasertib on CDR28, and the interaction with *PIK3CA* mutation status. Overall there was no difference in ctDNA suppression CDR28 between patients randomised to capivasertib and placebo, in the overall population (median CDR28 0.08 versus 0.12 respectively, *P *=* *0.904), nor in the *PIK3CA* mutant sub-population (CDR28 0.14 versus 0.06 respectively, *P *=* *0.071) (Figure [3](#mdz085-F3){ref-type="fig"}C, [supplementary Table S5](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Similarly, there was no difference in PFS between patients randomised to capivasertib and placebo, overall and in the *PIK3CA* mutant subpopulation (reported in the related article by Turner et al.).

Lead-time of sequential ctDNA tracking
--------------------------------------

Sequential ctDNA tracking through treatment may identify, in patients with initial treatment response, the time at which the tumour develops resistance to treatment anticipating clinical progression. In 50 patients in the part B randomised study, with sequential samples available for analysis, we tracked ctDNA mutations every 4 weeks throughout treatment to progression (Figure [4](#mdz085-F4){ref-type="fig"}A--C). Diverse dynamics were observed through treatment. In several patients ctDNA fell to a nadir at or below the limit of detection, before a clear rise in ctDNA occurred marking the development of resistance, with substantial lead-time over clinical progression (Figure [4](#mdz085-F4){ref-type="fig"}A). However, ctDNA dynamics were not easy to interpret in other patients, including patients with fluctuations around the nadir that made identification of the true rise challenging ('bumping along the bottom', Figure [4](#mdz085-F4){ref-type="fig"}B), and patients who had a slow rise from nadir making identification of the exact point of rise challenging ('slow rise', Figure [4](#mdz085-F4){ref-type="fig"}C). The 'bumping along the bottom' pattern likely reflected stochastic sampling issues with only relatively minor differences in total plasma DNA between timepoints ([supplementary Table S6](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

![Circulating tumour DNA (ctDNA) dynamics during treatment and lead-time over clinical progression. (A) Longitudinal tracking of a *PIK3CA c.1633G\>A* (p.E545K) mutation in a patient who demonstrates a clear fall to a sustained nadir and a clear rise before clinical progression. (B) Longitudinal tracking of a *PIK3CA c.3140 A\>G* (p.H1047R) mutation in a patient who demonstrates a fall in ctDNA which then fluctuates at a low level across multiple timepoints. (C) Longitudinal tracking of a *PIK3R1 DelCTGAGA* (p.L573_R574del) deletion in a patient who demonstrates a clear fall in ctDNA but a gradual rise over subsequent cycles before clinical progression. (D) Distribution of lead-time of calculated molecular progression before confirmed clinical progression (range 0--329 days).](mdz085f4){#mdz085-F4}

We defined criteria for ctDNA progression incorporating both 'rise from nadir' (Figure [4](#mdz085-F4){ref-type="fig"}) and 'rise towards baseline' ([supplementary Figure S2](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online) criteria (see Materials and methods). The rise from nadir criteria identified a median 3.1-month lead-time, whereas the alternative rise towards baseline formula identified a 2.6 median month lead time ([supplementary Figure S2](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). A lead-time over clinical progression was apparent in the majority of patients 74% (26/35) (Figure [4](#mdz085-F4){ref-type="fig"}D, [supplementary Figure S3](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online), although it did not report a lead-time over relapse in 26% (9/35) patients.

Clonal haematopoiesis of indeterminate potential is frequent in advanced breast cancer
--------------------------------------------------------------------------------------

To identify mutations to track in the validation cohort, plasma was sequenced with the AZ300 assay. Using this approach, 30% (18/59) of patients were classified as having evidence of detectable clonal haematopoiesis of indeterminate potential (CHIP) (Figure [5](#mdz085-F5){ref-type="fig"}A). CHIP was strongly suspected if a mutation was identified in the following genes: *DNMT3A*, *ASXL1*, *TET2*, *JAK2*, *SF3B1*, *CBL*, *GNAS*, and *IDH2* \[[@mdz085-B23]\]. *TP53* was not included in this analysis as this gene is commonly mutated in breast cancer, despite also being CHIP associated ([supplementary Figure S4](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Buffy coat germline DNA was not available to validate the CHIP variants. We investigated the clinical factors that associated with detection of potential CHIP, with prior anthracycline chemotherapy showing limited evidence of being positively associated with detection of CHIP (odds ratio 2.5; 95% confidence interval 0.69--8.9, Figure [5](#mdz085-F5){ref-type="fig"}B, *P *=* *0.155). The presence of CHIP had no effect on on-treatment nadir leukocytes (CHIP detected median 3.71 versus CHIP not detected median 3.05, *P *=* *0.12) nor nadir neutrophil count (CHIP detected median 1.63 versus CHIP not detected median 1.70 *P *=* *0.27). In a *PIK3CA* mutation-positive patient, we tracked a *DNMT3A* CHIP mutation through treatment demonstrating no change in allele fraction during treatment (Figure [5](#mdz085-F5){ref-type="fig"}C), despite a clear response in the *PIK3CA* mutation. PFS was similar in patients with baseline CHIP and without detected CHIP (Figure [5](#mdz085-F5){ref-type="fig"}D).

![Clonal haematopoiesis of indeterminate potential (CHIP) is frequently detected in advanced breast cancer. (A) Clonal haematopoiesis variants detected by sequencing of baseline plasma in part B. (B) Clinical and pathological associations of CHIP detection in baseline plasma. (C) Longitudinal tracking of a *PIK3CA c.3140 A\>G* (p.H1047R) mutation and a *DNMT3A* CHIP splice site donor *c.25236935 C\>T* variant in the same patient. (D) Progression-free survival by baseline detection of CHIP for the whole study population, capivasertib and placebo treatment arms. *P* values from log rank test.](mdz085f5){#mdz085-F5}

Discussion
==========

Circulating tumour DNA dynamics may present a more rapid way to assess efficacy of treatment than conventional cross-sectional imaging \[[@mdz085-B1], [@mdz085-B18], [@mdz085-B19]\]. In this study, we prospectively validated early ctDNA dynamics as a marker of treatment efficacy, demonstrating that early dynamics is a surrogate for PFS. We subsequently show that early ctDNA assessment predicted the results of the randomised phase II trial and correctly predicted that *PIK3CA* mutations did not identify ER+/HER2- cancers that were sensitive to AKT inhibition with capivasertib when combined with paclitaxel.

We show patients who suppress ctDNA after 4 weeks of treatment with paclitaxel with or without capivasertib have substantially improved PFS (Figure [3](#mdz085-F3){ref-type="fig"}A, [supplementary Figure S5](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). For patients with high ctDNA, this allows the identification of those patients who may benefit from an adaption in treatment. A few (approximately 9% 4/42) patients derived longer benefit from paclitaxel (\>200 days) despite high on-treatment ctDNA (high CDR28). In these patients, stopping paclitaxel on the basis of high CDR28 could conceivably be detrimental, and adaption to add in additional treatment may be more appropriate. Prospective randomised trials are required to assess whether early on-treatment treatment adaption has clinical utility.

Our data suggest that early ctDNA dynamics also represent a surrogate of targeted therapy efficacy when added to standard therapy. The BEECH study demonstrated that capivasertib added to paclitaxel did not improve PFS reported by Turner et al. \[[@mdz085-B22]\] in this population, and equally capivasertib did not result in greater early ctDNA suppression than placebo. In contrast, early ctDNA assessment in the PALOMA3 phase III study of fulvestrant and palbociclib or placebo demonstrated substantially improved PFS and ctDNA suppression with the addition of palbociclib. Therefore, early ctDNA dynamics has the potential to considerably improve decision making in early drug development, evaluating drug efficacy early, and assessing whether a biomarker (here *PIK3CA* mutation) predicts for targeted therapy efficacy.

Tracking ctDNA through treatment identifies a diversity of patterns of ctDNA progression. Patients with a sharp initial drop in ctDNA often demonstrate a clear rise that would appear to signify an event in the tumour that promotes resistance. However, identifying the rise in other patients is challenging due to variation along the nadir in responding tumours, largely reflecting stochastic sampling issues, or a slow rise from the nadir in other tumours. Developing a robust criterion to predict ctDNA rise and molecular resistance, essential for interventional studies triggered by ctDNA rise, was challenged by this diversity of ctDNA tracking patterns. Although the tracked mutations in this study are commonly clonal, we cannot account for the possibility that we tracked sub-clonal mutations that may show divergent dynamics during treatment compared with clonal mutations. Tracking multiple mutations could potentially resolve this but availability of material for further mutational analysis is limiting in this study \[[@mdz085-B8], [@mdz085-B12], [@mdz085-B26], [@mdz085-B27]\].

Our work identified frequent clonal haematopoiesis through ctDNA sequencing and identified prior adjuvant anthracycline chemotherapy exposure as a factor for the high prevalence in advanced breast cancer. Tolerance of chemotherapy was unaffected by CHIP, as was PFS \[[@mdz085-B28]\], suggesting that CHIP had no clinical consequence in these patients. Age was not a significant factor in our cohort, likely reflecting the dominant effect of prior chemotherapy in this cohort, in contrast with the effect of age in healthy volunteers reports \[[@mdz085-B23], [@mdz085-B24]\]. CHIP mutations remained constant tracking throughout treatment (Figure [5](#mdz085-F5){ref-type="fig"}C), emphasising the importance of not inadvertently tracking the dynamics of a CHIP mutation in an individual patient.

In summary, we show that early ctDNA dynamics is a strong surrogate end point for PFS and also provide a surrogate assessment of efficacy of add-on targeted therapies. Early ctDNA dynamics have the potential to inform individual treatment decisions and improve early drug development due to the potential to act as a surrogate of trial outcome.

Supplementary Material
======================

###### 

Click here for additional data file.
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